Prelude Therapeutics Investor Relations Material

Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, small molecule therapies targeting key drivers of cancer cell growth and resistance. Leveraging its expertise in cancer biology, medicinal chemistry, and drug development, Prelude Therapeutics is committed to advancing a pipeline of innovative treatments aimed at addressing the complex challenges of cancer treatment. The company is headquartered in Wilmington, Delaware, and its shares are listed on the Nasdaq.